Enoxaparin in the treatment of psoriasis

Abstract

Psoriasis is a chronic, immune-mediated inflammatory disease with diverse clinical manifestations and significant systemic burden. While current treatments, including biologics, offer effective control, limitations such as high cost, adverse effects, and resistance necessitate alternative options. Enoxaparin, a low-molecular-weight heparin, has shown promising anti-inflammatory and immunomodulatory effects at low, non-anticoagulant doses, particularly through its inhibition of T-cell activity, cytokine signaling, and keratinocyte proliferation. These mechanisms suggest its potential as an adjunct or alternative therapy in psoriasis management, warranting further clinical research to confirm its efficacy and safety in long-term use.